Literature DB >> 22859060

Disordered purinergic signaling and abnormal cellular metabolism are associated with development of liver cancer in Cd39/ENTPD1 null mice.

Xiaofeng Sun1, Lihui Han, Pankaj Seth, Shu Bian, Linglin Li, Eva Csizmadia, Wolfgang G Junger, Moritz Schmelzle, Anny Usheva, Elliot B Tapper, Gyorgy Baffy, Vikas P Sukhatme, Yan Wu, Simon C Robson.   

Abstract

UNLABELLED: Liver cancer is associated with chronic inflammation, which is linked to immune dysregulation, disordered metabolism, and aberrant cell proliferation. Nucleoside triphosphate diphosphohydrolase-1; (CD39/ENTPD1) is an ectonucleotidase that regulates extracellular nucleotide/nucleoside concentrations by scavenging nucleotides to ultimately generate adenosine. These properties inhibit antitumor immune responses and promote angiogenesis, being permissive for the growth of transplanted tumors. Here we show that Cd39 deletion promotes development of both induced and spontaneous autochthonous liver cancer in mice. Loss of Cd39 results in higher concentrations of extracellular nucleotides, which stimulate proliferation of hepatocytes, abrogate autophagy, and disrupt glycolytic metabolism. Constitutive activation of Ras-mitogen-activated protein kinase (MAPK) and mammalian target of rapamycin (mTOR)-S6K1 pathways occurs in both quiescent Cd39 null hepatocytes in vitro and liver tissues in vivo. Exogenous adenosine 5'-triphosphate (ATP) boosts these signaling pathways, whereas rapamycin inhibits such aberrant responses in hepatocytes.
CONCLUSION: Deletion of Cd39 and resulting changes in disordered purinergic signaling perturb hepatocellular metabolic/proliferative responses, paradoxically resulting in malignant transformation. These findings might impact adjunctive therapies for cancer. Our studies indicate that the biology of autochthonous and transplanted tumors is quite distinct.
Copyright © 2012 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22859060      PMCID: PMC3505255          DOI: 10.1002/hep.25989

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  34 in total

1.  The ER UDPase ENTPD5 promotes protein N-glycosylation, the Warburg effect, and proliferation in the PTEN pathway.

Authors:  Min Fang; Zhirong Shen; Song Huang; Liping Zhao; She Chen; Tak W Mak; Xiaodong Wang
Journal:  Cell       Date:  2010-11-11       Impact factor: 41.582

Review 2.  Ras, PI(3)K and mTOR signalling controls tumour cell growth.

Authors:  Reuben J Shaw; Lewis C Cantley
Journal:  Nature       Date:  2006-05-25       Impact factor: 49.962

3.  ATP release guides neutrophil chemotaxis via P2Y2 and A3 receptors.

Authors:  Yu Chen; Ross Corriden; Yoshiaki Inoue; Linda Yip; Naoyuki Hashiguchi; Annelies Zinkernagel; Victor Nizet; Paul A Insel; Wolfgang G Junger
Journal:  Science       Date:  2006-12-15       Impact factor: 47.728

4.  Senescence surveillance of pre-malignant hepatocytes limits liver cancer development.

Authors:  Tae-Won Kang; Tetyana Yevsa; Norman Woller; Lisa Hoenicke; Torsten Wuestefeld; Daniel Dauch; Anja Hohmeyer; Marcus Gereke; Ramona Rudalska; Anna Potapova; Marcus Iken; Mihael Vucur; Siegfried Weiss; Mathias Heikenwalder; Sadaf Khan; Jesus Gil; Dunja Bruder; Michael Manns; Peter Schirmacher; Frank Tacke; Michael Ott; Tom Luedde; Thomas Longerich; Stefan Kubicka; Lars Zender
Journal:  Nature       Date:  2011-11-09       Impact factor: 49.962

Review 5.  Ectonucleotidases of CD39 family modulate vascular inflammation and thrombosis in transplantation.

Authors:  Simon C Robson; Yan Wu; Xiaofeng Sun; Christoph Knosalla; Karen Dwyer; Keiichi Enjyoji
Journal:  Semin Thromb Hemost       Date:  2005-04       Impact factor: 4.180

6.  Vascular CD39/ENTPD1 directly promotes tumor cell growth by scavenging extracellular adenosine triphosphate.

Authors:  Lili Feng; Xiaofeng Sun; Eva Csizmadia; Lihui Han; Shu Bian; Takashi Murakami; Xin Wang; Simon C Robson; Yan Wu
Journal:  Neoplasia       Date:  2011-03       Impact factor: 5.715

7.  Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth.

Authors:  Taro Hitosugi; Sumin Kang; Matthew G Vander Heiden; Tae-Wook Chung; Shannon Elf; Katherine Lythgoe; Shaozhong Dong; Sagar Lonial; Xu Wang; Georgia Z Chen; Jianxin Xie; Ting-Lei Gu; Roberto D Polakiewicz; Johannes L Roesel; Titus J Boggon; Fadlo R Khuri; D Gary Gilliland; Lewis C Cantley; Jonathan Kaufman; Jing Chen
Journal:  Sci Signal       Date:  2009-11-17       Impact factor: 8.192

8.  Pivotal role of mTOR signaling in hepatocellular carcinoma.

Authors:  Augusto Villanueva; Derek Y Chiang; Pippa Newell; Judit Peix; Swan Thung; Clara Alsinet; Victoria Tovar; Sasan Roayaie; Beatriz Minguez; Manel Sole; Carlo Battiston; Stijn Van Laarhoven; Maria I Fiel; Analisa Di Feo; Yujin Hoshida; Steven Yea; Sara Toffanin; Alex Ramos; John A Martignetti; Vincenzo Mazzaferro; Jordi Bruix; Samuel Waxman; Myron Schwartz; Matthew Meyerson; Scott L Friedman; Josep M Llovet
Journal:  Gastroenterology       Date:  2008-08-20       Impact factor: 22.682

9.  Natural killer T cell dysfunction in CD39-null mice protects against concanavalin A-induced hepatitis.

Authors:  Guido Beldi; Yan Wu; Yara Banz; Michael Nowak; Lindsay Miller; Keiichi Enjyoji; Arvand Haschemi; Gennady G Yegutkin; Daniel Candinas; Mark Exley; Simon C Robson
Journal:  Hepatology       Date:  2008-09       Impact factor: 17.425

10.  Disruption of Id1 reveals major differences in angiogenesis between transplanted and autochthonous tumors.

Authors:  Hashmat Sikder; David L Huso; Hong Zhang; Binghe Wang; Byungwoo Ryu; Sam T Hwang; Jonathan D Powell; Rhoda M Alani
Journal:  Cancer Cell       Date:  2003-10       Impact factor: 31.743

View more
  46 in total

1.  Metabolic control of type 1 regulatory T cell differentiation by AHR and HIF1-α.

Authors:  Ivan D Mascanfroni; Maisa C Takenaka; Ada Yeste; Bonny Patel; Yan Wu; Jessica E Kenison; Shafiuddin Siddiqui; Alexandre S Basso; Leo E Otterbein; Drew M Pardoll; Fan Pan; Avner Priel; Clary B Clish; Simon C Robson; Francisco J Quintana
Journal:  Nat Med       Date:  2015-05-25       Impact factor: 53.440

2.  P2X7 Receptor Signaling Contributes to Sepsis-Associated Brain Dysfunction.

Authors:  Luiz Eduardo Baggio Savio; Mariana G Juste Andrade; Paola de Andrade Mello; Patrícia Teixeira Santana; Aline Cristina Abreu Moreira-Souza; Janaína Kolling; Aline Longoni; Linda Feldbrügge; Yan Wu; Angela T S Wyse; Simon C Robson; Robson Coutinho-Silva
Journal:  Mol Neurobiol       Date:  2016-10-11       Impact factor: 5.590

3.  Adenosine Kinase Deficiency Increases Susceptibility to a Carcinogen.

Authors:  Rkia El-Kharrag; Randy Owen; Detlev Boison
Journal:  J Caffeine Adenosine Res       Date:  2019-03-14

4.  The P2Y2 nucleotide receptor mediates the proliferation and migration of human hepatocellular carcinoma cells induced by ATP.

Authors:  Rui Xie; Jingyu Xu; Guorong Wen; Hai Jin; Xuemei Liu; Yuan Yang; Bei Ji; Yixia Jiang; Penghong Song; Hui Dong; Biguang Tuo
Journal:  J Biol Chem       Date:  2014-05-20       Impact factor: 5.157

Review 5.  Regulation of the T Cell Response by CD39.

Authors:  Maisa C Takenaka; Simon Robson; Francisco J Quintana
Journal:  Trends Immunol       Date:  2016-05-25       Impact factor: 16.687

6.  Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity.

Authors:  Xian-Yang Li; Achim K Moesta; Christos Xiao; Kyohei Nakamura; Mika Casey; Haiyan Zhang; Jason Madore; Ailin Lepletier; Amelia Roman Aguilera; Ashmitha Sundarrajan; Celia Jacoberger-Foissac; Clifford Wong; Tracy Dela Cruz; Megan Welch; Alana G Lerner; Bradley N Spatola; Vanessa B Soros; John Corbin; Ana C Anderson; Maike Effern; Michael Hölzel; Simon C Robson; Rebecca L Johnston; Nicola Waddell; Corey Smith; Tobias Bald; Nishamol Geetha; Courtney Beers; Michele W L Teng; Mark J Smyth
Journal:  Cancer Discov       Date:  2019-11-07       Impact factor: 39.397

Review 7.  Novel Targets for the Treatment of Melanoma.

Authors:  Lara Ambrosi; Shaheer Khan; Richard D Carvajal; Jessica Yang
Journal:  Curr Oncol Rep       Date:  2019-11-06       Impact factor: 5.075

Review 8.  Purinergic Signalling: Therapeutic Developments.

Authors:  Geoffrey Burnstock
Journal:  Front Pharmacol       Date:  2017-09-25       Impact factor: 5.810

Review 9.  Targeting CD39 in cancer.

Authors:  Achim K Moesta; Xian-Yang Li; Mark J Smyth
Journal:  Nat Rev Immunol       Date:  2020-07-29       Impact factor: 53.106

Review 10.  Hypoxia-inducible factors and innate immunity in liver cancer.

Authors:  Vincent Wai-Hin Yuen; Carmen Chak-Lui Wong
Journal:  J Clin Invest       Date:  2020-10-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.